nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—Degarelix—prostate cancer	0.39	1	CrCtD
Goserelin—GNRHR—Degarelix—prostate cancer	0.263	1	CbGbCtD
Goserelin—Cetrorelix—Degarelix—prostate cancer	0.0764	0.315	CrCrCtD
Goserelin—Ceruletide—Degarelix—prostate cancer	0.066	0.272	CrCrCtD
Goserelin—Nafarelin—Degarelix—prostate cancer	0.0524	0.216	CrCrCtD
Goserelin—Gonadorelin—Degarelix—prostate cancer	0.0477	0.197	CrCrCtD
Goserelin—LHCGR—renal system—prostate cancer	0.000148	0.485	CbGeAlD
Goserelin—LHCGR—testis—prostate cancer	9.55e-05	0.313	CbGeAlD
Goserelin—GNRHR—testis—prostate cancer	6.16e-05	0.202	CbGeAlD
Goserelin—LHCGR—GPCR downstream signaling—VAV3—prostate cancer	2.62e-05	0.000983	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PRKCQ—prostate cancer	2.59e-05	0.000973	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VIP—prostate cancer	2.57e-05	0.000967	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GNRH1—prostate cancer	2.57e-05	0.000967	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—GNG5—prostate cancer	2.54e-05	0.000953	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—ITPR1—prostate cancer	2.54e-05	0.000953	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GRP—prostate cancer	2.49e-05	0.000936	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—LPAR1—prostate cancer	2.49e-05	0.000936	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PLCB2—prostate cancer	2.47e-05	0.000927	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—LRP2—prostate cancer	2.47e-05	0.000927	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—ADRB2—prostate cancer	2.44e-05	0.000915	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PTHLH—prostate cancer	2.43e-05	0.000914	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—P4HB—prostate cancer	2.42e-05	0.000909	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CX3CL1—prostate cancer	2.42e-05	0.000909	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JUP—prostate cancer	2.38e-05	0.000895	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—WNT4—prostate cancer	2.38e-05	0.000895	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—VAV3—prostate cancer	2.38e-05	0.000892	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HIST1H2BG—prostate cancer	2.38e-05	0.000892	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GRB7—prostate cancer	2.35e-05	0.000884	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDE4D—prostate cancer	2.35e-05	0.000884	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—ITPR1—prostate cancer	2.3e-05	0.000866	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HIST1H4H—prostate cancer	2.29e-05	0.000862	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—CXCL8—prostate cancer	2.29e-05	0.000861	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ANXA1—prostate cancer	2.29e-05	0.00086	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RALBP1—prostate cancer	2.27e-05	0.000854	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MC2R—prostate cancer	2.27e-05	0.000854	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—GNG5—prostate cancer	2.24e-05	0.000841	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PTHLH—prostate cancer	2.21e-05	0.00083	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PRKACB—prostate cancer	2.16e-05	0.000813	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CALCA—prostate cancer	2.14e-05	0.000805	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PPP3CA—prostate cancer	2.11e-05	0.000792	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CXCL12—prostate cancer	2.09e-05	0.000786	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ANXA1—prostate cancer	2.08e-05	0.000781	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PENK—prostate cancer	2.03e-05	0.000761	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	2.02e-05	0.000757	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	1.99e-05	0.000747	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTHLH—prostate cancer	1.95e-05	0.000733	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TGFBR1—prostate cancer	1.95e-05	0.000733	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CALCA—prostate cancer	1.95e-05	0.000731	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GHR—prostate cancer	1.93e-05	0.000726	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—PIK3CA—prostate cancer	1.93e-05	0.000725	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKR1C3—prostate cancer	1.92e-05	0.000721	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PRKCQ—prostate cancer	1.91e-05	0.000718	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKACB—prostate cancer	1.91e-05	0.000717	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CXCL12—prostate cancer	1.9e-05	0.000714	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	1.88e-05	0.000706	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PPP3CA—prostate cancer	1.86e-05	0.000699	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—THBS1—prostate cancer	1.86e-05	0.000699	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NRP1—prostate cancer	1.85e-05	0.000696	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ANXA1—prostate cancer	1.83e-05	0.000689	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKCZ—prostate cancer	1.8e-05	0.000676	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ADRB2—prostate cancer	1.8e-05	0.000675	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CG—prostate cancer	1.76e-05	0.000661	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—VAV3—prostate cancer	1.75e-05	0.000658	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PARP1—prostate cancer	1.74e-05	0.000653	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGFR4—prostate cancer	1.74e-05	0.000653	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PRKCQ—prostate cancer	1.73e-05	0.000652	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	1.73e-05	0.000649	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GNRH1—prostate cancer	1.72e-05	0.000647	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VIP—prostate cancer	1.72e-05	0.000647	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CALCA—prostate cancer	1.72e-05	0.000645	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ITPR1—prostate cancer	1.7e-05	0.000638	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCL12—prostate cancer	1.68e-05	0.00063	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRP—prostate cancer	1.67e-05	0.000627	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—LPAR1—prostate cancer	1.67e-05	0.000627	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PLCB2—prostate cancer	1.65e-05	0.000621	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—LRP2—prostate cancer	1.65e-05	0.000621	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ADRB2—prostate cancer	1.63e-05	0.000613	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CX3CL1—prostate cancer	1.62e-05	0.000609	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—P4HB—prostate cancer	1.62e-05	0.000609	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—prostate cancer	1.6e-05	0.0006	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—VAV3—prostate cancer	1.59e-05	0.000597	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HIST1H2BG—prostate cancer	1.59e-05	0.000597	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CASP9—prostate cancer	1.58e-05	0.000593	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRB7—prostate cancer	1.58e-05	0.000592	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDE4D—prostate cancer	1.58e-05	0.000592	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—prostate cancer	1.55e-05	0.000581	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ITPR1—prostate cancer	1.54e-05	0.000579	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HIST1H4H—prostate cancer	1.54e-05	0.000577	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—CXCL8—prostate cancer	1.53e-05	0.000577	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKCQ—prostate cancer	1.53e-05	0.000575	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NGFR—prostate cancer	1.53e-05	0.000575	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	1.53e-05	0.000574	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAP3K7—prostate cancer	1.51e-05	0.000568	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GNG5—prostate cancer	1.5e-05	0.000563	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF10—prostate cancer	1.45e-05	0.000546	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADRB2—prostate cancer	1.44e-05	0.000541	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—JAK2—prostate cancer	1.42e-05	0.000533	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—MAP2K1—prostate cancer	1.41e-05	0.000531	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—prostate cancer	1.4e-05	0.000528	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VAV3—prostate cancer	1.4e-05	0.000527	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TGFBR2—prostate cancer	1.38e-05	0.00052	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ITPR1—prostate cancer	1.36e-05	0.000511	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—prostate cancer	1.35e-05	0.000506	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFBR1—prostate cancer	1.31e-05	0.000491	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTHLH—prostate cancer	1.31e-05	0.000491	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IGF1R—prostate cancer	1.3e-05	0.000489	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CXCL8—prostate cancer	1.3e-05	0.000487	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—JAK2—prostate cancer	1.29e-05	0.000484	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKR1C3—prostate cancer	1.28e-05	0.000483	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKACB—prostate cancer	1.28e-05	0.00048	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—LPL—prostate cancer	1.25e-05	0.000469	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PPP3CA—prostate cancer	1.25e-05	0.000468	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—THBS1—prostate cancer	1.25e-05	0.000468	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—IL2—prostate cancer	1.24e-05	0.000465	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFRB—prostate cancer	1.24e-05	0.000465	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ANXA1—prostate cancer	1.23e-05	0.000461	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—prostate cancer	1.22e-05	0.00046	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKCZ—prostate cancer	1.2e-05	0.000453	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ITGB3—prostate cancer	1.2e-05	0.000453	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—prostate cancer	1.18e-05	0.000442	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL8—prostate cancer	1.18e-05	0.000442	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB3—prostate cancer	1.17e-05	0.000439	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGFR2—prostate cancer	1.17e-05	0.000438	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PARP1—prostate cancer	1.16e-05	0.000437	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGFR4—prostate cancer	1.16e-05	0.000437	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CALCA—prostate cancer	1.15e-05	0.000432	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL2—prostate cancer	1.12e-05	0.000422	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL12—prostate cancer	1.12e-05	0.000422	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—prostate cancer	1.12e-05	0.000421	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HIF1A—prostate cancer	1.07e-05	0.000402	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—prostate cancer	1.07e-05	0.000402	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CASP9—prostate cancer	1.06e-05	0.000397	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—LEP—prostate cancer	1.05e-05	0.000393	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CAV1—prostate cancer	1.04e-05	0.000389	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—prostate cancer	1.04e-05	0.000389	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKCQ—prostate cancer	1.02e-05	0.000385	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KDR—prostate cancer	1.02e-05	0.000385	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NGFR—prostate cancer	1.02e-05	0.000385	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAP3K7—prostate cancer	1.01e-05	0.00038	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ESR1—prostate cancer	9.98e-06	0.000375	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BAD—prostate cancer	9.75e-06	0.000366	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF10—prostate cancer	9.73e-06	0.000366	CbGpPWpGaD
Goserelin—Epistaxis—Doxorubicin—prostate cancer	9.66e-06	0.000125	CcSEcCtD
Goserelin—Anorexia—Capecitabine—prostate cancer	9.66e-06	0.000125	CcSEcCtD
Goserelin—Nausea—Estradiol—prostate cancer	9.65e-06	0.000125	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ADRB2—prostate cancer	9.63e-06	0.000362	CbGpPWpGaD
Goserelin—Vomiting—Mitoxantrone—prostate cancer	9.63e-06	0.000125	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—prostate cancer	9.61e-06	0.000124	CcSEcCtD
Goserelin—Convulsion—Prednisone—prostate cancer	9.58e-06	0.000124	CcSEcCtD
Goserelin—Hypertension—Prednisone—prostate cancer	9.55e-06	0.000124	CcSEcCtD
Goserelin—Rash—Mitoxantrone—prostate cancer	9.55e-06	0.000124	CcSEcCtD
Goserelin—Dermatitis—Mitoxantrone—prostate cancer	9.54e-06	0.000124	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.54e-06	0.000124	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—JAK2—prostate cancer	9.5e-06	0.000357	CbGpPWpGaD
Goserelin—Headache—Mitoxantrone—prostate cancer	9.49e-06	0.000123	CcSEcCtD
Goserelin—Hypotension—Capecitabine—prostate cancer	9.47e-06	0.000123	CcSEcCtD
Goserelin—Insomnia—Docetaxel—prostate cancer	9.47e-06	0.000123	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—MAP2K1—prostate cancer	9.46e-06	0.000356	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—prostate cancer	9.44e-06	0.000355	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—APC—prostate cancer	9.44e-06	0.000355	CbGpPWpGaD
Goserelin—Myalgia—Prednisone—prostate cancer	9.42e-06	0.000122	CcSEcCtD
Goserelin—Arthralgia—Prednisone—prostate cancer	9.42e-06	0.000122	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—prostate cancer	9.4e-06	0.000353	CbGpPWpGaD
Goserelin—Paraesthesia—Docetaxel—prostate cancer	9.4e-06	0.000122	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—VAV3—prostate cancer	9.39e-06	0.000353	CbGpPWpGaD
Goserelin—Anxiety—Prednisone—prostate cancer	9.38e-06	0.000122	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.35e-06	0.000121	CcSEcCtD
Goserelin—Dyspnoea—Docetaxel—prostate cancer	9.33e-06	0.000121	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IRS1—prostate cancer	9.33e-06	0.00035	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGF—prostate cancer	9.33e-06	0.00035	CbGpPWpGaD
Goserelin—Somnolence—Docetaxel—prostate cancer	9.3e-06	0.000121	CcSEcCtD
Goserelin—Discomfort—Prednisone—prostate cancer	9.3e-06	0.00012	CcSEcCtD
Goserelin—Eye disorder—Epirubicin—prostate cancer	9.29e-06	0.00012	CcSEcCtD
Goserelin—Hypersensitivity—Etoposide—prostate cancer	9.28e-06	0.00012	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—TGFBR2—prostate cancer	9.26e-06	0.000348	CbGpPWpGaD
Goserelin—Haemoglobin—Doxorubicin—prostate cancer	9.24e-06	0.00012	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.23e-06	0.00012	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—prostate cancer	9.22e-06	0.000119	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—prostate cancer	9.22e-06	0.000119	CcSEcCtD
Goserelin—Dyspepsia—Docetaxel—prostate cancer	9.21e-06	0.000119	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—prostate cancer	9.19e-06	0.000119	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—prostate cancer	9.19e-06	0.000119	CcSEcCtD
Goserelin—Insomnia—Capecitabine—prostate cancer	9.17e-06	0.000119	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—prostate cancer	9.13e-06	0.000118	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ITPR1—prostate cancer	9.11e-06	0.000342	CbGpPWpGaD
Goserelin—Paraesthesia—Capecitabine—prostate cancer	9.1e-06	0.000118	CcSEcCtD
Goserelin—Decreased appetite—Docetaxel—prostate cancer	9.1e-06	0.000118	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—prostate cancer	9.08e-06	0.000118	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—prostate cancer	9.06e-06	0.000117	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—GSK3B—prostate cancer	9.06e-06	0.00034	CbGpPWpGaD
Goserelin—Asthenia—Etoposide—prostate cancer	9.04e-06	0.000117	CcSEcCtD
Goserelin—Dyspnoea—Capecitabine—prostate cancer	9.03e-06	0.000117	CcSEcCtD
Goserelin—Oedema—Prednisone—prostate cancer	9.03e-06	0.000117	CcSEcCtD
Goserelin—Anaphylactic shock—Prednisone—prostate cancer	9.03e-06	0.000117	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—prostate cancer	9.02e-06	0.000339	CbGpPWpGaD
Goserelin—Fatigue—Docetaxel—prostate cancer	9.02e-06	0.000117	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—prostate cancer	9.02e-06	0.000117	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—prostate cancer	9.01e-06	0.000117	CcSEcCtD
Goserelin—Nausea—Mitoxantrone—prostate cancer	8.99e-06	0.000116	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—prostate cancer	8.98e-06	0.000116	CcSEcCtD
Goserelin—Infection—Prednisone—prostate cancer	8.97e-06	0.000116	CcSEcCtD
Goserelin—Pain—Docetaxel—prostate cancer	8.95e-06	0.000116	CcSEcCtD
Goserelin—Constipation—Docetaxel—prostate cancer	8.95e-06	0.000116	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—INS—prostate cancer	8.93e-06	0.000336	CbGpPWpGaD
Goserelin—Dyspepsia—Capecitabine—prostate cancer	8.92e-06	0.000116	CcSEcCtD
Goserelin—Chills—Epirubicin—prostate cancer	8.92e-06	0.000115	CcSEcCtD
Goserelin—Pruritus—Etoposide—prostate cancer	8.91e-06	0.000115	CcSEcCtD
Goserelin—Shock—Prednisone—prostate cancer	8.88e-06	0.000115	CcSEcCtD
Goserelin—Arrhythmia—Epirubicin—prostate cancer	8.88e-06	0.000115	CcSEcCtD
Goserelin—Nervous system disorder—Prednisone—prostate cancer	8.85e-06	0.000115	CcSEcCtD
Goserelin—Tachycardia—Prednisone—prostate cancer	8.81e-06	0.000114	CcSEcCtD
Goserelin—Decreased appetite—Capecitabine—prostate cancer	8.81e-06	0.000114	CcSEcCtD
Goserelin—Alopecia—Epirubicin—prostate cancer	8.78e-06	0.000114	CcSEcCtD
Goserelin—Skin disorder—Prednisone—prostate cancer	8.77e-06	0.000114	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CREBBP—prostate cancer	8.75e-06	0.000329	CbGpPWpGaD
Goserelin—Fatigue—Capecitabine—prostate cancer	8.74e-06	0.000113	CcSEcCtD
Goserelin—Hyperhidrosis—Prednisone—prostate cancer	8.73e-06	0.000113	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IGF1R—prostate cancer	8.71e-06	0.000327	CbGpPWpGaD
Goserelin—Mental disorder—Epirubicin—prostate cancer	8.71e-06	0.000113	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCL8—prostate cancer	8.67e-06	0.000326	CbGpPWpGaD
Goserelin—Pain—Capecitabine—prostate cancer	8.67e-06	0.000112	CcSEcCtD
Goserelin—Constipation—Capecitabine—prostate cancer	8.67e-06	0.000112	CcSEcCtD
Goserelin—Erythema—Epirubicin—prostate cancer	8.65e-06	0.000112	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—prostate cancer	8.65e-06	0.000112	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IGF1—prostate cancer	8.64e-06	0.000325	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—JAK2—prostate cancer	8.63e-06	0.000324	CbGpPWpGaD
Goserelin—Feeling abnormal—Docetaxel—prostate cancer	8.62e-06	0.000112	CcSEcCtD
Goserelin—Diarrhoea—Etoposide—prostate cancer	8.62e-06	0.000112	CcSEcCtD
Goserelin—Anorexia—Prednisone—prostate cancer	8.6e-06	0.000111	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—EGFR—prostate cancer	8.6e-06	0.000323	CbGpPWpGaD
Goserelin—Eye disorder—Doxorubicin—prostate cancer	8.59e-06	0.000111	CcSEcCtD
Goserelin—Gastrointestinal pain—Docetaxel—prostate cancer	8.56e-06	0.000111	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—prostate cancer	8.53e-06	0.000111	CcSEcCtD
Goserelin—Flatulence—Epirubicin—prostate cancer	8.52e-06	0.00011	CcSEcCtD
Goserelin—Tension—Epirubicin—prostate cancer	8.49e-06	0.00011	CcSEcCtD
Goserelin—Nervousness—Epirubicin—prostate cancer	8.4e-06	0.000109	CcSEcCtD
Goserelin—Back pain—Epirubicin—prostate cancer	8.37e-06	0.000108	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—LPL—prostate cancer	8.35e-06	0.000314	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAP2K1—prostate cancer	8.35e-06	0.000314	CbGpPWpGaD
Goserelin—Feeling abnormal—Capecitabine—prostate cancer	8.35e-06	0.000108	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—prostate cancer	8.34e-06	0.000108	CcSEcCtD
Goserelin—Dizziness—Etoposide—prostate cancer	8.33e-06	0.000108	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—prostate cancer	8.32e-06	0.000108	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—prostate cancer	8.3e-06	0.000108	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—prostate cancer	8.3e-06	0.000312	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—prostate cancer	8.29e-06	0.000311	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Capecitabine—prostate cancer	8.29e-06	0.000107	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PDGFRB—prostate cancer	8.28e-06	0.000311	CbGpPWpGaD
Goserelin—Abdominal pain—Docetaxel—prostate cancer	8.27e-06	0.000107	CcSEcCtD
Goserelin—Body temperature increased—Docetaxel—prostate cancer	8.27e-06	0.000107	CcSEcCtD
Goserelin—Chills—Doxorubicin—prostate cancer	8.25e-06	0.000107	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Prednisone—prostate cancer	8.22e-06	0.000107	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—prostate cancer	8.22e-06	0.000309	CbGpPWpGaD
Goserelin—Arrhythmia—Doxorubicin—prostate cancer	8.21e-06	0.000106	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SERPINE1—prostate cancer	8.21e-06	0.000308	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—prostate cancer	8.2e-06	0.000308	CbGpPWpGaD
Goserelin—Insomnia—Prednisone—prostate cancer	8.16e-06	0.000106	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—prostate cancer	8.15e-06	0.000106	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—prostate cancer	8.12e-06	0.000105	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—KRAS—prostate cancer	8.12e-06	0.000305	CbGpPWpGaD
Goserelin—Paraesthesia—Prednisone—prostate cancer	8.11e-06	0.000105	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ITGB3—prostate cancer	8.07e-06	0.000303	CbGpPWpGaD
Goserelin—Mental disorder—Doxorubicin—prostate cancer	8.05e-06	0.000104	CcSEcCtD
Goserelin—Urticaria—Capecitabine—prostate cancer	8.05e-06	0.000104	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—prostate cancer	8.03e-06	0.000104	CcSEcCtD
Goserelin—Body temperature increased—Capecitabine—prostate cancer	8.01e-06	0.000104	CcSEcCtD
Goserelin—Abdominal pain—Capecitabine—prostate cancer	8.01e-06	0.000104	CcSEcCtD
Goserelin—Vomiting—Etoposide—prostate cancer	8.01e-06	0.000104	CcSEcCtD
Goserelin—Erythema—Doxorubicin—prostate cancer	8e-06	0.000104	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—prostate cancer	8e-06	0.000104	CcSEcCtD
Goserelin—Anaemia—Epirubicin—prostate cancer	7.99e-06	0.000104	CcSEcCtD
Goserelin—Dyspepsia—Prednisone—prostate cancer	7.95e-06	0.000103	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—FGF2—prostate cancer	7.94e-06	0.000298	CbGpPWpGaD
Goserelin—Rash—Etoposide—prostate cancer	7.94e-06	0.000103	CcSEcCtD
Goserelin—Dermatitis—Etoposide—prostate cancer	7.93e-06	0.000103	CcSEcCtD
Goserelin—Headache—Etoposide—prostate cancer	7.89e-06	0.000102	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—prostate cancer	7.89e-06	0.000102	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—CXCL8—prostate cancer	7.88e-06	0.000296	CbGpPWpGaD
Goserelin—Tension—Doxorubicin—prostate cancer	7.85e-06	0.000102	CcSEcCtD
Goserelin—Decreased appetite—Prednisone—prostate cancer	7.85e-06	0.000102	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—NOS3—prostate cancer	7.83e-06	0.000294	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB3—prostate cancer	7.82e-06	0.000294	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGFR2—prostate cancer	7.81e-06	0.000293	CbGpPWpGaD
Goserelin—Malaise—Epirubicin—prostate cancer	7.8e-06	0.000101	CcSEcCtD
Goserelin—Fatigue—Prednisone—prostate cancer	7.78e-06	0.000101	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—prostate cancer	7.77e-06	0.000101	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—prostate cancer	7.74e-06	0.0001	CcSEcCtD
Goserelin—Back pain—Doxorubicin—prostate cancer	7.74e-06	0.0001	CcSEcCtD
Goserelin—Constipation—Prednisone—prostate cancer	7.72e-06	0.0001	CcSEcCtD
Goserelin—Hypersensitivity—Docetaxel—prostate cancer	7.71e-06	9.99e-05	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—prostate cancer	7.69e-06	9.97e-05	CcSEcCtD
Goserelin—Palpitations—Epirubicin—prostate cancer	7.64e-06	9.9e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—JAK2—prostate cancer	7.61e-06	0.000286	CbGpPWpGaD
Goserelin—Cough—Epirubicin—prostate cancer	7.55e-06	9.78e-05	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—prostate cancer	7.54e-06	9.77e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL2—prostate cancer	7.53e-06	0.000283	CbGpPWpGaD
Goserelin—Asthenia—Docetaxel—prostate cancer	7.51e-06	9.73e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—TERT—prostate cancer	7.5e-06	0.000282	CbGpPWpGaD
Goserelin—Convulsion—Epirubicin—prostate cancer	7.49e-06	9.71e-05	CcSEcCtD
Goserelin—Nausea—Etoposide—prostate cancer	7.48e-06	9.69e-05	CcSEcCtD
Goserelin—Hypertension—Epirubicin—prostate cancer	7.47e-06	9.67e-05	CcSEcCtD
Goserelin—Hypersensitivity—Capecitabine—prostate cancer	7.47e-06	9.67e-05	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—prostate cancer	7.46e-06	0.00028	CbGpPWpGaD
Goserelin—Feeling abnormal—Prednisone—prostate cancer	7.44e-06	9.63e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MDM2—prostate cancer	7.43e-06	0.000279	CbGpPWpGaD
Goserelin—Ill-defined disorder—Doxorubicin—prostate cancer	7.43e-06	9.62e-05	CcSEcCtD
Goserelin—Pruritus—Docetaxel—prostate cancer	7.4e-06	9.59e-05	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—prostate cancer	7.4e-06	9.58e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Prednisone—prostate cancer	7.38e-06	9.56e-05	CcSEcCtD
Goserelin—Chest pain—Epirubicin—prostate cancer	7.36e-06	9.54e-05	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—prostate cancer	7.36e-06	9.54e-05	CcSEcCtD
Goserelin—Myalgia—Epirubicin—prostate cancer	7.36e-06	9.54e-05	CcSEcCtD
Goserelin—Anxiety—Epirubicin—prostate cancer	7.34e-06	9.5e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—ERBB2—prostate cancer	7.33e-06	0.000275	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.31e-06	9.47e-05	CcSEcCtD
Goserelin—Discomfort—Epirubicin—prostate cancer	7.28e-06	9.42e-05	CcSEcCtD
Goserelin—Asthenia—Capecitabine—prostate cancer	7.27e-06	9.42e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—prostate cancer	7.23e-06	0.000272	CbGpPWpGaD
Goserelin—Malaise—Doxorubicin—prostate cancer	7.22e-06	9.35e-05	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—prostate cancer	7.2e-06	9.33e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HIF1A—prostate cancer	7.17e-06	0.000269	CbGpPWpGaD
Goserelin—Urticaria—Prednisone—prostate cancer	7.17e-06	9.29e-05	CcSEcCtD
Goserelin—Pruritus—Capecitabine—prostate cancer	7.17e-06	9.29e-05	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—prostate cancer	7.16e-06	9.28e-05	CcSEcCtD
Goserelin—Diarrhoea—Docetaxel—prostate cancer	7.16e-06	9.28e-05	CcSEcCtD
Goserelin—Abdominal pain—Prednisone—prostate cancer	7.14e-06	9.24e-05	CcSEcCtD
Goserelin—Body temperature increased—Prednisone—prostate cancer	7.14e-06	9.24e-05	CcSEcCtD
Goserelin—Confusional state—Epirubicin—prostate cancer	7.12e-06	9.22e-05	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—prostate cancer	7.07e-06	9.16e-05	CcSEcCtD
Goserelin—Oedema—Epirubicin—prostate cancer	7.06e-06	9.14e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—prostate cancer	7.06e-06	9.14e-05	CcSEcCtD
Goserelin—Infection—Epirubicin—prostate cancer	7.01e-06	9.08e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—LEP—prostate cancer	7e-06	0.000263	CbGpPWpGaD
Goserelin—Cough—Doxorubicin—prostate cancer	6.98e-06	9.05e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CXCL8—prostate cancer	6.95e-06	0.000261	CbGpPWpGaD
Goserelin—Shock—Epirubicin—prostate cancer	6.95e-06	9e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CAV1—prostate cancer	6.94e-06	0.000261	CbGpPWpGaD
Goserelin—Convulsion—Doxorubicin—prostate cancer	6.93e-06	8.98e-05	CcSEcCtD
Goserelin—Diarrhoea—Capecitabine—prostate cancer	6.93e-06	8.98e-05	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—prostate cancer	6.92e-06	8.97e-05	CcSEcCtD
Goserelin—Dizziness—Docetaxel—prostate cancer	6.92e-06	8.96e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—prostate cancer	6.91e-06	8.95e-05	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—prostate cancer	6.91e-06	8.95e-05	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—prostate cancer	6.89e-06	8.92e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—KDR—prostate cancer	6.86e-06	0.000258	CbGpPWpGaD
Goserelin—Skin disorder—Epirubicin—prostate cancer	6.86e-06	8.88e-05	CcSEcCtD
Goserelin—Hyperhidrosis—Epirubicin—prostate cancer	6.82e-06	8.84e-05	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—prostate cancer	6.81e-06	8.83e-05	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—prostate cancer	6.81e-06	8.83e-05	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—prostate cancer	6.81e-06	8.83e-05	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—prostate cancer	6.79e-06	8.79e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—prostate cancer	6.79e-06	0.000255	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.77e-06	8.76e-05	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—prostate cancer	6.73e-06	8.72e-05	CcSEcCtD
Goserelin—Anorexia—Epirubicin—prostate cancer	6.73e-06	8.72e-05	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—prostate cancer	6.71e-06	0.000252	CbGpPWpGaD
Goserelin—Dizziness—Capecitabine—prostate cancer	6.7e-06	8.68e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ESR1—prostate cancer	6.68e-06	0.000251	CbGpPWpGaD
Goserelin—Dry mouth—Doxorubicin—prostate cancer	6.66e-06	8.63e-05	CcSEcCtD
Goserelin—Vomiting—Docetaxel—prostate cancer	6.65e-06	8.62e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CASP3—prostate cancer	6.65e-06	0.00025	CbGpPWpGaD
Goserelin—Hypersensitivity—Prednisone—prostate cancer	6.65e-06	8.61e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL2—prostate cancer	6.64e-06	0.00025	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6—prostate cancer	6.61e-06	0.000248	CbGpPWpGaD
Goserelin—Rash—Docetaxel—prostate cancer	6.6e-06	8.55e-05	CcSEcCtD
Goserelin—Hypotension—Epirubicin—prostate cancer	6.6e-06	8.54e-05	CcSEcCtD
Goserelin—Dermatitis—Docetaxel—prostate cancer	6.59e-06	8.54e-05	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—prostate cancer	6.59e-06	8.53e-05	CcSEcCtD
Goserelin—Headache—Docetaxel—prostate cancer	6.56e-06	8.49e-05	CcSEcCtD
Goserelin—Oedema—Doxorubicin—prostate cancer	6.53e-06	8.46e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—prostate cancer	6.53e-06	8.46e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—BAD—prostate cancer	6.52e-06	0.000245	CbGpPWpGaD
Goserelin—Infection—Doxorubicin—prostate cancer	6.49e-06	8.4e-05	CcSEcCtD
Goserelin—Asthenia—Prednisone—prostate cancer	6.48e-06	8.39e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CCND1—prostate cancer	6.47e-06	0.000243	CbGpPWpGaD
Goserelin—Vomiting—Capecitabine—prostate cancer	6.44e-06	8.34e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.43e-06	8.33e-05	CcSEcCtD
Goserelin—Shock—Doxorubicin—prostate cancer	6.43e-06	8.32e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CTNNB1—prostate cancer	6.41e-06	0.000241	CbGpPWpGaD
Goserelin—Nervous system disorder—Doxorubicin—prostate cancer	6.41e-06	8.3e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—prostate cancer	6.4e-06	8.28e-05	CcSEcCtD
Goserelin—Rash—Capecitabine—prostate cancer	6.39e-06	8.28e-05	CcSEcCtD
Goserelin—Pruritus—Prednisone—prostate cancer	6.39e-06	8.27e-05	CcSEcCtD
Goserelin—Insomnia—Epirubicin—prostate cancer	6.39e-06	8.27e-05	CcSEcCtD
Goserelin—Dermatitis—Capecitabine—prostate cancer	6.38e-06	8.27e-05	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—prostate cancer	6.38e-06	8.26e-05	CcSEcCtD
Goserelin—Headache—Capecitabine—prostate cancer	6.35e-06	8.22e-05	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—prostate cancer	6.34e-06	8.22e-05	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—prostate cancer	6.34e-06	8.21e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—prostate cancer	6.32e-06	0.000237	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—APC—prostate cancer	6.32e-06	0.000237	CbGpPWpGaD
Goserelin—Hyperhidrosis—Doxorubicin—prostate cancer	6.31e-06	8.18e-05	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—prostate cancer	6.29e-06	8.15e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MMP9—prostate cancer	6.29e-06	0.000236	CbGpPWpGaD
Goserelin—Somnolence—Epirubicin—prostate cancer	6.28e-06	8.13e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN1A—prostate cancer	6.26e-06	0.000235	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—prostate cancer	6.25e-06	0.000235	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGF—prostate cancer	6.25e-06	0.000235	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IRS1—prostate cancer	6.25e-06	0.000235	CbGpPWpGaD
Goserelin—Anorexia—Doxorubicin—prostate cancer	6.23e-06	8.06e-05	CcSEcCtD
Goserelin—Nausea—Docetaxel—prostate cancer	6.22e-06	8.05e-05	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—prostate cancer	6.21e-06	8.05e-05	CcSEcCtD
Goserelin—Diarrhoea—Prednisone—prostate cancer	6.18e-06	8e-05	CcSEcCtD
Goserelin—Decreased appetite—Epirubicin—prostate cancer	6.14e-06	7.95e-05	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—prostate cancer	6.1e-06	7.91e-05	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—AKT1—prostate cancer	6.1e-06	0.000229	CbGpPWpGaD
Goserelin—Fatigue—Epirubicin—prostate cancer	6.09e-06	7.88e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—GSK3B—prostate cancer	6.06e-06	0.000228	CbGpPWpGaD
Goserelin—Pain—Epirubicin—prostate cancer	6.04e-06	7.82e-05	CcSEcCtD
Goserelin—Constipation—Epirubicin—prostate cancer	6.04e-06	7.82e-05	CcSEcCtD
Goserelin—Nausea—Capecitabine—prostate cancer	6.02e-06	7.8e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—INS—prostate cancer	5.98e-06	0.000225	CbGpPWpGaD
Goserelin—Dizziness—Prednisone—prostate cancer	5.97e-06	7.73e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EP300—prostate cancer	5.96e-06	0.000224	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.95e-06	7.71e-05	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—prostate cancer	5.91e-06	7.65e-05	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—prostate cancer	5.87e-06	7.6e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CREBBP—prostate cancer	5.86e-06	0.00022	CbGpPWpGaD
Goserelin—Dyspnoea—Doxorubicin—prostate cancer	5.82e-06	7.54e-05	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—prostate cancer	5.82e-06	7.53e-05	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—prostate cancer	5.81e-06	7.52e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SRC—prostate cancer	5.8e-06	0.000218	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IGF1—prostate cancer	5.79e-06	0.000217	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Epirubicin—prostate cancer	5.77e-06	7.48e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—EGFR—prostate cancer	5.76e-06	0.000216	CbGpPWpGaD
Goserelin—Dyspepsia—Doxorubicin—prostate cancer	5.75e-06	7.45e-05	CcSEcCtD
Goserelin—Vomiting—Prednisone—prostate cancer	5.74e-06	7.43e-05	CcSEcCtD
Goserelin—Rash—Prednisone—prostate cancer	5.69e-06	7.37e-05	CcSEcCtD
Goserelin—Dermatitis—Prednisone—prostate cancer	5.69e-06	7.36e-05	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—prostate cancer	5.68e-06	7.35e-05	CcSEcCtD
Goserelin—Headache—Prednisone—prostate cancer	5.65e-06	7.32e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—VEGFA—prostate cancer	5.64e-06	0.000212	CbGpPWpGaD
Goserelin—Fatigue—Doxorubicin—prostate cancer	5.63e-06	7.29e-05	CcSEcCtD
Goserelin—Urticaria—Epirubicin—prostate cancer	5.61e-06	7.26e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MAP2K1—prostate cancer	5.59e-06	0.00021	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT3—prostate cancer	5.59e-06	0.00021	CbGpPWpGaD
Goserelin—Pain—Doxorubicin—prostate cancer	5.59e-06	7.23e-05	CcSEcCtD
Goserelin—Constipation—Doxorubicin—prostate cancer	5.59e-06	7.23e-05	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—prostate cancer	5.58e-06	7.23e-05	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—prostate cancer	5.58e-06	7.23e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—prostate cancer	5.55e-06	0.000209	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—prostate cancer	5.5e-06	0.000207	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SERPINE1—prostate cancer	5.49e-06	0.000206	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—KRAS—prostate cancer	5.44e-06	0.000204	CbGpPWpGaD
Goserelin—Feeling abnormal—Doxorubicin—prostate cancer	5.38e-06	6.97e-05	CcSEcCtD
Goserelin—Nausea—Prednisone—prostate cancer	5.36e-06	6.94e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—prostate cancer	5.34e-06	6.92e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FGF2—prostate cancer	5.32e-06	0.0002	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NOS3—prostate cancer	5.24e-06	0.000197	CbGpPWpGaD
Goserelin—Hypersensitivity—Epirubicin—prostate cancer	5.2e-06	6.74e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MYC—prostate cancer	5.19e-06	0.000195	CbGpPWpGaD
Goserelin—Urticaria—Doxorubicin—prostate cancer	5.19e-06	6.72e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—TGFB1—prostate cancer	5.18e-06	0.000195	CbGpPWpGaD
Goserelin—Body temperature increased—Doxorubicin—prostate cancer	5.16e-06	6.69e-05	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—prostate cancer	5.16e-06	6.69e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—JAK2—prostate cancer	5.1e-06	0.000192	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGFR—prostate cancer	5.08e-06	0.000191	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—prostate cancer	5.07e-06	6.56e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—prostate cancer	5e-06	0.000188	CbGpPWpGaD
Goserelin—Pruritus—Epirubicin—prostate cancer	4.99e-06	6.47e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MDM2—prostate cancer	4.98e-06	0.000187	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB2—prostate cancer	4.91e-06	0.000184	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—prostate cancer	4.84e-06	0.000182	CbGpPWpGaD
Goserelin—Diarrhoea—Epirubicin—prostate cancer	4.83e-06	6.26e-05	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—prostate cancer	4.81e-06	6.23e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—KRAS—prostate cancer	4.8e-06	0.00018	CbGpPWpGaD
Goserelin—Asthenia—Doxorubicin—prostate cancer	4.69e-06	6.07e-05	CcSEcCtD
Goserelin—Dizziness—Epirubicin—prostate cancer	4.67e-06	6.05e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CXCL8—prostate cancer	4.65e-06	0.000175	CbGpPWpGaD
Goserelin—Pruritus—Doxorubicin—prostate cancer	4.62e-06	5.99e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—prostate cancer	4.54e-06	0.000171	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—prostate cancer	4.49e-06	0.000169	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—prostate cancer	4.49e-06	5.81e-05	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—prostate cancer	4.47e-06	5.79e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CASP3—prostate cancer	4.45e-06	0.000167	CbGpPWpGaD
Goserelin—Rash—Epirubicin—prostate cancer	4.45e-06	5.77e-05	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—prostate cancer	4.45e-06	5.76e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IL2—prostate cancer	4.45e-06	0.000167	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6—prostate cancer	4.42e-06	0.000166	CbGpPWpGaD
Goserelin—Headache—Epirubicin—prostate cancer	4.42e-06	5.73e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—prostate cancer	4.41e-06	0.000166	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCND1—prostate cancer	4.33e-06	0.000163	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—prostate cancer	4.32e-06	5.59e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CTNNB1—prostate cancer	4.29e-06	0.000161	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—prostate cancer	4.26e-06	0.00016	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP9—prostate cancer	4.21e-06	0.000158	CbGpPWpGaD
Goserelin—Nausea—Epirubicin—prostate cancer	4.19e-06	5.43e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1A—prostate cancer	4.19e-06	0.000158	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—prostate cancer	4.18e-06	0.000157	CbGpPWpGaD
Goserelin—Vomiting—Doxorubicin—prostate cancer	4.15e-06	5.38e-05	CcSEcCtD
Goserelin—Rash—Doxorubicin—prostate cancer	4.12e-06	5.33e-05	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—prostate cancer	4.11e-06	5.33e-05	CcSEcCtD
Goserelin—Headache—Doxorubicin—prostate cancer	4.09e-06	5.3e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—AKT1—prostate cancer	4.08e-06	0.000153	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EP300—prostate cancer	3.99e-06	0.00015	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL6—prostate cancer	3.9e-06	0.000147	CbGpPWpGaD
Goserelin—Nausea—Doxorubicin—prostate cancer	3.88e-06	5.03e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SRC—prostate cancer	3.88e-06	0.000146	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFA—prostate cancer	3.78e-06	0.000142	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT3—prostate cancer	3.74e-06	0.000141	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT1—prostate cancer	3.6e-06	0.000135	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MYC—prostate cancer	3.48e-06	0.000131	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFB1—prostate cancer	3.47e-06	0.00013	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—prostate cancer	3.4e-06	0.000128	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—prostate cancer	3.21e-06	0.000121	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—prostate cancer	2.95e-06	0.000111	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—prostate cancer	2.86e-06	0.000107	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6—prostate cancer	2.61e-06	9.82e-05	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—prostate cancer	2.41e-06	9.06e-05	CbGpPWpGaD
